Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc (NCNA) is a clinical-stage biopharmaceutical company pioneering ProTide technology to develop enhanced cancer therapeutics. This page provides investors and researchers with essential updates on clinical trials, regulatory developments, and scientific advancements related to NuCana's innovative approach to overcoming chemotherapy resistance.
Key resources include: Press releases detailing clinical progress, analyses of pipeline candidates for solid tumors, and updates on phosphoramidate chemistry applications. Users will find verified information on drug safety profiles, trial designs, and strategic collaborations.
Regular updates cover:
- Phase I-III clinical trial results
- Regulatory submissions and FDA communications
- Scientific conference presentations
- Intellectual property developments
Bookmark this page for structured access to NuCana's latest advancements in reengineering conventional chemotherapy agents through proprietary nucleotide analog technology. Check back for objective reporting on innovations designed to improve intracellular drug activation in cancer cells.
NuCana plc (NASDAQ: NCNA) will feature its executives Hugh Griffith and Don Munoz in three virtual investor conferences in September 2021. The events include Citi’s 16th Annual BioPharma Virtual Conference from September 8-10, the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, and Oppenheimer’s Virtual Fall Healthcare Life Sciences & MedTech Summit on September 22, with a live presentation at 9:05 AM ET. Webcasts of the presentations will be available on the company's website post-event.
NuCana plc (NASDAQ: NCNA) reported its Q2 2021 financial results, showing a net loss of £9.1 million, widening from £6.1 million in Q2 2020. Cash reserves decreased to £73.4 million from £78.6 million in Q1 2021. The company continues to expand its clinical programs, particularly the NuTide studies on NUC-3373 and NUC-7738. Looking ahead, NuCana anticipates key milestones in 2022, including interim data analysis for Acelarin, potentially enabling an NDA submission under the FDA’s accelerated approval. New Chief Medical Officer, Dr. Jeffrey Bloss, joins to aid in development efforts.
NuCana plc announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer to enhance its leadership team. Dr. Bloss, with over 25 years in oncology, has played a role in developing and commercializing numerous oncology drugs. He is expected to support the advancement of NuCana’s ProTide pipeline, which includes ongoing Phase III studies for Acelarin and NUC-3373. The company aims to improve treatment outcomes for cancer patients through innovative therapies.
NuCana plc (NASDAQ: NCNA) has announced that CEO Hugh Griffith and CFO Don Munoz will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. Their presentation is scheduled for June 1, 2021, at 9:30 AM ET, and will be available for live webcasting on the company's website under 'Events & Presentations'. NuCana is focused on enhancing cancer treatment outcomes through its ProTide technology, with clinical developments including Acelarin, NUC-3373, and NUC-7738 targeting various cancers.
NuCana (NASDAQ: NCNA) reported first-quarter results for 2021, revealing a net loss of £9.8 million, compared to £4.0 million in Q1 2020. Cash and equivalents fell to £78.6 million from £87.4 million. The company noted a 62% disease control rate for NUC-3373 in colorectal cancer at the ASCO-GI symposium, alongside promising findings from AACR on NUC-7738. In 2021, NuCana aims to advance multiple clinical trials, including a Phase III study of Acelarin and additional studies for NUC-3373. Strong clinical data is expected to enhance treatment outcomes for cancer patients.
NuCana plc (NASDAQ: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will participate in one-on-one meetings at the 7th Annual Truist Securities Life Sciences Summit on May 4-5, 2021. NuCana focuses on advancing cancer treatment through its ProTide technology, aiming to improve efficacy and safety of chemotherapy agents. Its pipeline includes three ProTides: Acelarin, in Phase III for advanced biliary tract and pancreatic cancer; NUC-3373, in Phase I/IB for various advanced solid tumors; and NUC-7738, in Phase I for advanced solid tumors.
NuCana plc (NASDAQ: NCNA) reported promising findings from presentations at the AACR Annual Meeting 2021. The data highlights the efficacy of NUC-3373 in advanced colorectal cancer, showing a 62% disease control rate among 38 patients, with no severe toxicities. NUC-7738 demonstrated anti-cancer activity in advanced solid tumors and high levels of the active metabolite 3’-dATP. Additionally, Acelarin showed persistent DNA damage in biliary tract cancer cells. These advances showcase NuCana's innovative ProTide technology aimed at enhancing cancer treatment outcomes.
NuCana plc (NASDAQ: NCNA) reported its financial results for Q4 and the year ended December 31, 2020, showing a net loss of £30.7 million, up from £21.4 million in 2019. Cash reserves declined to £87.4 million from £100.7 million in Q3 2020. The company raised $80 million in a follow-on offering to strengthen its balance sheet. Encouraging clinical data for NUC-3373 and NUC-7738 were highlighted, along with continued enrollment in the Phase III biliary tract cancer study (NuTide:121). New board appointments were also announced, aiming to enhance strategic direction.
NuCana plc (Nasdaq: NCNA) announced participation in several upcoming healthcare conferences. Hugh Griffith (CEO) and Don Munoz (CFO) will present at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 1:30 PM ET, and at the Oppenheimer's 31st Annual Healthcare Conference on March 18, 2021, at 9:20 AM ET. The presentations will be webcast live and available for replay on the company's website. NuCana focuses on developing enhanced cancer therapies using its proprietary ProTide technology, aiming to improve outcomes for patients with various types of cancer.
NuCana (NASDAQ: NCNA) reported interim data from its NuTide:302 study at the ASCO GI Conference, revealing a promising 62% disease control rate and notable tumor shrinkage in heavily pre-treated metastatic colorectal cancer patients. The study evaluated NUC-3373, a thymidylate synthase inhibitor, for safety and efficacy. The drug exhibited a favorable safety profile, with no severe side effects compared to traditional therapies like 5-FU. Clinical data highlighted individual cases showing significant tumor reductions, suggesting NUC-3373's potential as a new backbone treatment.
